Haemophilia

Volume 18 Issue 5, September 2012

Commemorative Article

Review Articles
655 Acquired, non-amyloid related factor X deficiency: review of the literature. G. Lee, W. Duan-Porter and A. Metjian

Commentary

Editorial
685 Is it justifiable to transplant infected livers into haemophilia recipients? I. A. Rowe, J. T. Wilde and D. Mutimer

Original Articles
Clinical haemophilia
688 Mortality, health care utilization and associated diagnoses in hospitalized patients with haemophilia in the United States: first reported nationwide estimates. R. Goel and L. Krishnamurti

Laboratory science

Musculoskeletal
818 The potential role of synovial thrombomodulin in the pathophysiology of joint bleeds in haemophilia. Y. Dargaud, H. Simpson, Y. Chevalier, J. Y. Scoazec, A. Hot, O. Guyen
Table of Contents

Haemophilia

T. Baglin and C. Négrier

Transfusion transmitted disease

824 Intrafamilial transmission of hepatitis C virus in patients with severe haemophilia A.
  A. C. A. Culasso, N. Aloisi, M. Candela, R. H. Campos and P. Baré

Abstracts

828 Late-Breaking Abstracts from the WFH 2012 Hemophilia World Congress.

Online Letters

834 Platelet inhibition and bleeding complications in patients with haemophilia/von Willebrand’s disease and coronary artery disease.
  S. Alesci, S. Krekeler, E. Seifried and W. Muesbach

836 The importance of haemophilia treatment centre administrators in patient care.

837 Efficacy evaluation of products for treatment of bleeding episodes.
  C. Kisker, L. Aledort and H. Farin

839 Abdominal pain in a patient with haemophilia and metallic valve replacement.
  R. Everett, S. Ahmed and M. Laffan


841 Late-Breaking Abstracts from the WFH 2012 Hemophilia World Congress.

Volume 18 Issue 6, November 2012

Commemorative Article

833 Judith Graham Pool and the discovery of cryoprecipitate.
  C. K. Kasper

Review Articles

836 Opinions on radiosynovectomy for chronic haemophilic synovitis: point/counterpoint.
  M. Silva, J. V. Luck and C. Leissinger

843 The effect of cooling on coagulation and haemostasis: Should “Ice” be part of treatment of acute haemarthrosis in haemophilia?

Original Articles

Clinical haemophilia

851 Registry of Hemophilia and other bleeding disorders in Syria.
  T. Ali and J. F. Schved

855 Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
  K. Lindvall, J. Asterman, S. Bjorkman, R. Ljung, K. S. Carlsson, S. Persson and E. Bernsorp

860 Determinants of participation in patients with severe haemophilia.
  F. R. van Genderen, N. L. U. van Meeteren, K. Fischer and P. J. M. Holders

868 Prevalence of depression in adults with haemophilia.

875 The development of a patient partnership programme and its impact on quality improvements in a comprehensive haemophilia care service.
  A. Grogan, M. Coughlan, B. O’Maloney and G. McKee

Pharmacokinetic properties of IB1001, an investigational recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with haemophilia B.
  H. S. Kang, W. O. Kim, Y. Jeong, S. Y. Kim and K. Y. Yoo

881 Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.

884 Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.

888 Medical radiation exposure in children with bleeding disorders: an institutional experience.
  C. C. Crawford, S. L. Meeks and A. L. Dunn

  H. S. Kang, W. O. Kim, Y. Jeong, S. Y. Kim and K. Y. Yoo

898 The impact of sport on children with haemophilia.

900 Feasibility of short message service to document bleeding episodes.
  A. C. A. Culasso, N. Aloisi, M. Candela, R. H. Campos and P. Baré

906 Rare coagulation disorders: a study of 70 cases in the Egyptian population.
  M. Abdelwahab and N. Khaddah

908 Late immune tolerance induction in an adult with severe haemophilia A and high-responder inhibitor: 1-year outcome.
  A. Faradji, G. Lavigne-Lissalde, L. Grunebaum, D. Desprez, O. Feugeas and P. Lapalud

912 Allergenic vaccines administration and inhibitor development in haemophilia.
  N. Bermejo, C. Martín Aguilea, F. Carnicero and J. Bergua
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>e426</td>
<td>Corrigendum</td>
</tr>
<tr>
<td>e420</td>
<td>Pattern of bleeding and response to therapy in Glanzmann thrombasthenia.</td>
</tr>
<tr>
<td>e418</td>
<td>Joint distraction: a treatment to consider for haemophilic arthropathy.</td>
</tr>
<tr>
<td>e416</td>
<td>Immune system polymorphisms and factor VIII inhibitor formation in children with haemophilia.</td>
</tr>
<tr>
<td>e414</td>
<td>Arthroscopic synovectomy of the elbow covered with rFVIIa in a haemophilia B juvenile with inhibitor.</td>
</tr>
<tr>
<td>e412</td>
<td>Factor VIII inhibitors in patients with congenital severe haemophilia A and its relation to genotype.</td>
</tr>
<tr>
<td>e410</td>
<td>Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors.</td>
</tr>
<tr>
<td>e405</td>
<td>Trauma-related bleeding complications in South African patients with haemophilia.</td>
</tr>
<tr>
<td>e403</td>
<td>A Canadian survey of self-infusion practices in persons with haemophilia A.</td>
</tr>
<tr>
<td>e401</td>
<td>Regional registry of bleeding disorders in Tunisia.</td>
</tr>
<tr>
<td>e400</td>
<td>Large psosas haematoma and femoral neuropathy in a patient with type 2B von Willebrand’s disease.</td>
</tr>
<tr>
<td>e399</td>
<td>Reply to von Willebrand’s disease and postpartum haemorrhage by Chee et al.</td>
</tr>
<tr>
<td>e397</td>
<td>Mutation spectrum and inhibitor risk in 100 Korean patients with severe haemophilia A.</td>
</tr>
<tr>
<td>e396</td>
<td>Online Letters</td>
</tr>
</tbody>
</table>

### Laboratory science

911 Feasibility of using thrombin generation assay (TGA) for monitoring of haemostasis during supplementation therapy in haemophilic patients without inhibitors.

Y. Ay, C. Balkan, D. Y. Karapinar, M. Akin, B. Bileroğlu and K. Kavakli

917 The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studies in vitro.

F. A. Ofori, H. Tse, A. Naqui, H. Bliakta and Y. Song

926 Evaluation of a novel flow chamber system to assess clot formation in factor VIII-deficient mouse and anti-factor IXa-treated human blood.

S. Ogawa, F. Saltan, A. L. Dunn, D. Bolliger, T. Ohtsuki, K. Hosokawa and K. A. Tanaka

### Genetics

933 Analysis of F9 point mutations and their correlation to severity of haemophilia B disease.


941 Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.

H. Aguero, H. R. Stemnicke, H. Pelzer, E. N. Olsen, E. P. Merricks, N. A. de Fries, T. C. Nichols and M. Ezban

### Musculoskeletal

948 Ankle muscle activation in people with haemophilia.

E. Kurz, C. Anders, M. Herbsleb, C. Puta, D. Czepa and T. Hilberg

955 Peripheral quantitative computed tomography (pQCT) reveals alterations in the three-dimensional bone structure in children with haemophilia.

S. Ranta, H. Viljakainen, A. Mäkipermaa and O. Mäkitie

962 An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group.


### Inhibitors


982 Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.

S. Grancha, A. M. Ortiz, L. Avilés, A. Moret, P. Salaj, P. Ovesna, M. Penka and U. Hedner

### Kinetics

997 Experience of recombinant activated factor VII usage during surgery in patients with haemophilia with inhibitors.

T. Polyomatskaya, V. Zorenko, E. Karpov, M. Sampiev, G. Mishin and D. Vasiliev

1003 Polymorphic mRNA-mediated gene contribution to inhibitor development in haemophilia A.

V. Bafanoo, R. Santacroce, M. Chetta, F. Peyvandi, F. Sessa, E. Chinmi, V. Longo and M. Margaglione

1008 Mutation spectrum and inhibitor risk in 100 Korean patients with severe haemophilia A.


### Announcement

1014 6th Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) 6–8 February 2013, Warsaw, Poland.